Grupo Espanol De Tumores Neuroendocrinos

This study is testing whether a newer, targeted radiation therapy (177Lu-edotreotide) works better than the standard drug everolimus to control advanced neuroendocrine tumors in the lung and thymus. It will involve 120 adults whose tumors have specific markers and have progressed…

This study is testing a new immunotherapy drug called tarlatamab for people with advanced neuroendocrine cancer of the digestive system. The goal is to see if the drug, given alone or with standard chemotherapy, can help patients live longer by activating their own immune system …

This study is for people with a specific type of slow-growing digestive tract cancer. It is testing if giving the same radioactive drug treatment less often (every 16 weeks instead of every 8 weeks) can cause fewer serious side effects, especially blood-related problems, while st…